Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which High-Tech camera is better at spotting skin cancer?

NCT ID NCT07740642

Knowledge-focused Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 31, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This study compares two total body photography systems used to screen for melanoma, a serious skin cancer. One system, Deviskan, takes automated images with non-contact dermoscopy, while the other, Vectra WB360, uses 3D photography with manual dermoscopy. Researchers will ask 60 people at high risk for melanoma about their sense of safety with each system, and also measure how long each examination takes. The goal is to understand which system patients and dermatologists prefer and which is more efficient in a real-world setting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Two total body skin imaging systems: Deviskan (automated non-contact dermoscopy) and Vectra WB360 (3D photography with manual dermoscopy)
What this could lead to
If one system proves more efficient and preferred, it could become a standard tool for melanoma screening, potentially improving early detection.
What could go wrong
This is a small usability study, not a test of diagnostic accuracy. Preferences and time savings may not translate to better health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Signed informed consent by the participant * Sufficient proficiency in German * At least one of the following risk criteria for melanoma: * Previous melanoma (including in situ) * Suspected melanoma * ≥ 100 common naevi * ≥ 5 dysplastic naevi * dysplastic naevus syndrome * Known CDKN2A mutation * Strong family history for melanoma (≥ first- and/or second-degree relatives) Exclusion Criteria: * Lack of informed consent * Immobility. (Patients must be able to stand without support for 30 minutes.) * Inability to follow the procedures of the investigation, including inability to follow on-screen instructions or to read (e.g. due to visual impairment or cognitive impairment) * Vulnerable Subjects * Active skin conditions that may impact the performance of TBP systems or skin cancer screenings * Cardiac pacemaker * Pregnant women (self reported, no pregnancy test planned) * Height below 150 cm or above 195 cm * Severe Claustrophobia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Melanoma (skin cancer) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Melanoma (skin cancer)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital Basel

    Basel, Canton of Basel-City, 4055, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.